share this

Hizentra 200mg/ml Solution for Subcutaneous Injection

Hizentra 200mg/ml Solution for Subcutaneous Injection, Human Normal Immunoglobulin is indicated for:

Replacement therapy in adults, children and adolescents (0-18 years) in:

  • Primary immunodeficiency syndromes with impaired antibody production (see section 4.4),
  • Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated,
  • Hypogammaglobulinaemia and recurrent infections in multiple myeloma (MM) patients,
  • Hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation (HSCT).

Hizentra is available in the following presentations:

  • 1g in 5ml vial
  • 2g in 10ml vial
  • 4g in 20ml vial

For further information please refer to our Hizentra Brochure here and the product SPC. For details on Hizentra at Home, our homecare services programme please click here.

Please visit our Privigen page for information on our Solution for Infusion, Human Normal Immunoglobulin.

Method of Sale: POM

License Number: EU/1/11/687/001, EU/1/11/687/004 & EU/1/11/687/010

MAH Holder: CSL Behring GmbH

Emil-von-Behring-Strasse 76

D-35041 Marburg

Germany

For any further information please speak to your local Fannin Representative or for a copy of the SPC please contact our medical information department at medical@dccvital.com or via phone on 086 839 4447.

Hizentra is distributed in Ireland by Fannin Ltd. in partnership with CSL Behring(This link will take you to a non-Fannin Ltd. website.  Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties.) 

 IE2017/058/00    Date of Preparation: October 2017

ROI orders / enquiries please contact

+353 1 2907000

+353 1 2907111

Pharma orders / enquiries please contact

+35312907000

+35312907111